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ABSTRACT
Past and ongoing therapeutic concepts for ulcerative
colitis have only been moderately successful.
A significant proportion of patients with ulcerative colitis
will still have to undergo colectomy and overall half of
the patients do not achieve sustained remission, leading
to impairment of physical and mental health, social life,
employment issues and sexual activity. Reluctance to
treat patients early on with sufficiently potent drug
regimens is obvious. Several popular misconceptions
might have led to this situation. First, ulcerative colitis is
still considered a more ‘benign’ disease than Crohn’s
disease. Furthermore, the general assumption is often
that colectomy can ‘cure’ the disease. Mucosal healing
as a therapeutic target has not been widely accepted.
Finally, the use of antitumour necrosis factor antibodies
in ulcerative colitis has been low because this treatment
is considered to be less effective than in Crohn’s disease.
In the current review we try to disprove these
misunderstandings by discussing relevant studies
showing how harmful this disease can be and explaining
why future studies targeting sustained suppression of
inflammation could have an enormous impact on the
natural course of the disease. Until these studies are
available, we encourage physicians to intensify and
maintain treatment until sustained remission and
mucosal healing has been reached.
INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory
bowel disease of uncertain aetiology, with an inci-
dence of 0.5e24.5 per 100 000 individuals per year1
and the highest estimates observed in the age
group 20e35.2 The site of inflammation is the
mucosal layer of the colon, but occasionally deeper
layers can become inflamed. The disease almost
always involves the rectum and from there
continuously more proximal parts of the large
bowel. At diagnosis, one-third of all patients with
UC have distal colitis or proctosigmoiditis, one-
third have left-sided colitis and one-third more
proximal or pan-colitis.3 4 Between 15% and 30% of
all patients with left-sided disease suffer from
extension to more proximal colonic segments.3 4
The prevailing symptoms depend on the anatomic
extent and the severity of inflammation. Most
patients experience recurrent episodes of rectal
bleeding, passage of mucus, increased stool
frequency, abdominal cramps and pain. More severe
cases may develop fever, anaemia and weight loss.
The combination of symptoms, endoscopic
appearance and radiography determine the severity
of the disease. In many patients longstanding
chronic inflammation leads to structural damage
of the large bowel5 6 with impaired function and
an enhanced risk of colorectal cancer.7 Amino-
salicylates, corticosteroids, purine analogues and
infliximab are the cornerstones of medical treat-
ment for UC. The efficacy of adalimumab is
currently under investigation. Between 5% and
50% of patients undergo colectomy during the
course of the disease, mostly with an ileal
poucheanal anastomosis (IPAA).8 The wide varia-
tion in surgical rates can be explained by the
availability of biological treatments, local and
national guidelines and cultural differences.
The management of UC is undergoing significant
changes. One aspect that has received more atten-
tion lately is the importance of mucosal healing.
Already in 1923, however, Sir Arthur F Hurst, one
of the first authors to describe UC,9 concluded in an
article10 that ‘no case of UC can be regarded as
cured until the sigmoidoscope shows that the
mucous membrane is perfectly healthy’. This
treatment goal got lost or seems to have been
ignored in the meantime by several generations of
physicians. A century later, the role of mucosal
integrity has again moved into the centre of
interest.
Another paradigm shift has brought more
attention to maintenance treatment. While it was
generally accepted for decades that patients with
UC only need treatment when symptoms occur,
the idea of continued treatment that minimises or
eliminates inflammation and reduces the risk of
relapse now finds increasing support.11 The idea
that the destructive effect of chronic inflammation
in the gut is ongoing, even if patients do not have
major symptoms is, however, well founded.12
National guidelines that have been developed in
Europe and elsewhere have mainly focused on
when and how to use steroids, aminosalicylates
and surgery.13 Only late in the course of the disease,
immunosuppressants and tumour necrosis factor
(TNF) blockers have been introduced rather hesi-
tantly, even long after their advent on the market.
The main concerns relate to the potential toxicity
of the newer agents without paying attention to
the harm caused by prolonged corticosteroid use or
undertreatment. In a number of European countries
there is the assumption among gastroenterologists
and surgeons that TNF blockers should be offered
only as an alternative to colectomy.
As the medical professionals taking care of
patients with UC, we have to admit that our
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treatment concepts have not been very successful.
Ongoing disease activity is present in w50% of all
patients with UC, colectomy rates remain high,
and absence from social activities, unemployment,
impaired quality of life, sick leave and disability
pensions are higher in patients with UC than in the
general population.14
Could it be that misunderstandings and
misconceptions have led to this rather unsuccessful
outcome? The current paper is an attempt to list
and critically review our potential misunderstand-
ings and strategic views and to offer guidelines for
more optimal care in the future.
CURRENT MISUNDERSTANDINGS
UC is a ‘benign’ disease: colectomy, mortality and
remission rates
The assumption that UC is a ‘benign’ disease can
easily be refuted by the current colectomy rates.
European studies recently reported a 10-year
cumulative colectomy risk of 9%15 with a slight
gradient from northern to southern European
centres.15 16 In a paediatric cohort study in 113
children aged 0e17 years, the calculated cumulative
rate of colectomy was even 20% at 5 years.17 It
takes a lot of euphemism to call a disease ‘benign’
when it leads to organ loss in 1 in 10 patients.
In addition, the so far largest meta-analysis18 of
>10 000patients with UC in 10 studies recently
found a greater mortality risk in patients with more
than distal UC as compared with the respective
background population (RR 1.2, 95% CI 1.0 to 1.5,
p¼0.047). The majority of patients with UC
present with more than distal colitis, as was shown
in the IBSEN cohort.3 Of 519 patients, 33% had
proctitis, 35% left-sided colitis and 32% extensive
colitis at diagnosis. In another large meta-anal-
ysis,19 patients with UC were also found to be at an
increased risk of cancer of the liver and biliary
system (RR 2.58, 95% CI 1.58 to 4.22), an obser-
vation possibly related to the relatively frequent
occurrence of primary sclerosing cholangitis in
patients with UC.
In the landmark study by Langholz et al, that
looked at the outcomes of patients with UC over
25 years from 1962 until 1987 (when amino-
salicylates and steroids were the only drugs used),
only 25% of patients in the 3e7 years after first
diagnosis were in remission, 57% of patients had
intermittent and 18% had continuous activity.20
Within a median observation period of 3 years, 77%
of the patients had at least one second flare.
Colectomy rates at 10 years were 24%.
As already mentioned, in the Norwegian IBSEN
cohort study3 423 patients with UC were asked to
categorise their clinical course for the previous
10 years using one out of four predefined curves
(figure 1). Twelve per cent of patients could not
choose a curve because they had already been
colectomised. The remaining patients selected
curve 3 or 4 in 43% of the cases, which means
that w50% of the patients had an unfavourable
course of the disease (either colectomy or chronic
continuous or chronic intermittent symptoms). It
is difficult to understand why the authors
concluded that patients with newly diagnosed UC
have an overall good prognosis during the first
10 years of disease.
In an interesting recent survey in North America,
450 patients with UC and 300 gastroenterologists
were asked independently how they perceived the
impact of UC.21 Patients reported, on average, eight
flares per year, while gastroenterologists estimated
the annual relapse frequency at three. Sixty-two
per cent of patients with UC reported that their
disease made it difficult to lead a normal life,
compared with gastroenterologists’ estimations of
36%. Most surprisingly, only 42% of patients
believed that being in remission could mean living
without symptoms. The same authors compared
the answers to health-related questions of the
patients with UC with those of >900 patients with
rheumatoid arthritis, asthma and migraine.22
Patients with UC reported significantly more
worries about disease complications, depression
and embarrassment than patients with the other
chronic conditions.
Another way to look at severity of UC is to look
at therapeutic outcome following treatment for an
acute relapse. In many clinical trials, investigators
have used ‘response’ rates as an end point, whereas
recent guidelines have recommended using more
strict criteria such as remission rates in combina-
tion with mucosal healing. Physicians advising
patients on their therapeutic options based on
results in clinical trials must be aware that most
indices used in these trials did not define remission
as the total absence of any symptoms.23 For
example in the ACT trials,24 remission was defined
as a Mayo score of up to 2 points with no indi-
vidual subscore exceeding 1 point, which means
that patients could be considered in remission in
the presence of mild disease activity with subtle
bleeding or diarrhoea.
Three typical patient populations have been
examined in clinical trials for UC: (1) the mostly
untreated patients with a mild to moderate flare;
(2) mesalamine-refractory patients; and (3) steroid-
and/or immunosuppressant-refractory patients.
In patients with a flare of mild to moderate UC
who had not been treated with >2 g of mesalazine
the two most recent global UC trials with a new
mesalazine preparation were performed by Kamm
and Lichtenstein and later published again in
a combined analysis.25e27 Of the 517 patients,
8-week complete mucosal healing rates were 35%
and 37% with two doses of mesalazine (4.8 and
2.4 g/day), compared with 18% on placebo. This
means that although 40% had mild disease and 80%
had only left-sided colitis, only about one-third of
these patients was brought into remission after
8 weeks of treatment. If a sigmoidoscopy end point
score of 0 had been chosendthat is, a healthy
mucosadless than half of these patients would
have reached remission. This means that the
ideal outcome of a symptom-free state with fully
healed mucosa is achieved in <20% of cases in this
type of patient.
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If mesalazine fails, systemic steroids are usually
introduced. In such a situation, remission rates at
30 days were 54%, based on a retrospective analysis
describing the natural history of steroid treatment
for UC.28 Mucosal healing after treatment with
corticosteroids has not been investigated.29
More than 700 patients with active UC who
were either steroid dependent or refractory, or
refractory to immunosuppressives were treated
with the TNF-blocking agent infliximab (Remicade,
Centocor/MSD) in the ACT trials.24 Remission
rates at week 30 were as low as 30% and 36% for 5
and 10 mg/kg infliximab, respectively. Surprisingly,
mucosal healing rates at the same time point were
as high as 48% and 53%, with mucosal healing
defined as a Mayo subscore for endoscopy of 0 or 1.
Patients with mucosal healing (Mayo grade 0) at
week 8 were more likely to be in clinical remission
at week 30.30 In both ACT trials, the most potent
anti-inflammatory agent currently available, inflix-
imab, brought only one out of three patients into
remission, not taking into consideration that
one-third of these patients were still receiving
steroids in addition.
In summary, the perception that UC is a benign
disease is not justified. UC is a disease that leads to
organ loss in 5e25% of cases, is associated with
increased mortality and has a negative impact on
daily life. The drugs that we use and the way in
which we use them do not bring the majority of
affected patients into ‘remission’, which is the most
desirable outcome. UC is a potentially aggressive,
mostly undertreated and sometimes lethal chronic
disease. Only a minority of patients experience
a disease course that can be called ‘benign’.
UC can be ‘cured’ by colectomy
When all medical treatment options have been
exhausted, patients with intractable or badly
controllable UC usually undergo colectomy. A total
proctocolectomy with IPAA8 has become the
procedure of choice for intractable UC and also in
the case of dysplasia or cancer. Some authors have
even suggested to ‘move up’ surgery to an earlier
therapeutic step as a form of ‘top-down’
approach.31 Although it is often stated that by
removing the colon normal life can be restored in
all patients, this is unfortunately rarely the case.
Studies that assessed health-related quality of life
in a postcolectomy UC population generally
reported an improvement after surgery. However,
most of these surveys looked at patients with the
most severe forms of UC and are characterised by
a rather short-term follow-up.32 33
Looking a bit further down the line, however,
a variety of complications can occur after surgery.
Pouchitis, pouch leakage, pelvic abscesses, pouch
fistulae, small bowel obstruction, anastomotic
stricture, postoperative bleeding, faecal inconti-
nence, sexual dysfunction and female infertility
are frequent. A recent retrospective analysis of the
Leuven IBD group in >180 patients with UC
who underwent proctocolectomy in 1990e2004
described the outcome after IPAA.34 Within
1 month after closure of ileostomy, 27% of all
patients developed at least one complication. After
a median follow-up time of 6.5 years, sepsis was
seen in 14% and obstructive complications in 26%
of all patients, respectively, with 5% of the patients
having both septic and obstructive complications.
Another retrospective chart review of 31 paediatric
patients with UC who underwent colectomy
reported obstructive complications in 16% and
fistulas in 16% within a mean observation period
of 4.5 years.35
The most common complication is pouchitis
In the Leuven cohort34 (median follow-up of
6.5 years), 46% of patients developed at least one
episode of acute pouchitis. Of these patients, 40%
developed fewer than three episodes of pouchitis
during follow-up, 19% had acute relapsing
pouchitis and 41% developed chronic pouchitis.
This means that relapsing or chronic inflammation
in the pouch occurred in >1 in 4 of all patients with
IPAA. Their global pouch failure rate was 5%. In
a German single centre cohort review, pouch failure
rates of even 13% at a median follow-up of 12 years
were reported.36 Lichtenstein and colleagues stated
that 1 in 6 of their patients with IPAA required
reversal and had a conventional ileostomy.37
Furthermore, even with a ‘successful’ pouch,
functional results are far from the ‘normal situa-
tion’. In the Leuven cohort,34 50% of patients with
IPAA had more than five bowel movements per day
and 25% had more than two bowel movements at
night. Soiling or seepage at night was reported by
15% and the IBD-related ongoing need for contin-
uous or occasional medication by 35%. In a recently
published Swiss study with a similar design, 107
patients were evaluated for their functional results
after IPAA within a median follow-up period of
7 years.38 Sixty-six per cent of patients reported
Figure 1 Results of the Norwegian IBSEN cohort study. A total of 423 patients with
ulcerative colitis were asked to categorise their clinical course for the previous 10 years
using one out of four predefined curves (reproduced from Solberg et al3).
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5e10 bowel movements per day and 73% had at
least one movement during the night. Twenty-five
per cent had episodes of soiling. Night time
continence was excellent in only 41% of patients.
In a recent meta-analysis39 of seven studies,
female fertility in 481 patients with IPAA was
compared with that in 411 patients with UC
without IPAA. In the surgical group, the risk of
infertility was increased from 15% to 48%. The
authors concluded that these findings may
encourage physicians to consider even potentially
hazardous rescue treatments including ciclosporin
and infliximab, before submitting young women
to colectomy. Indeed, if at all possible, pouch
construction should be postponed until a female
patient has had as many pregnancies as desired.
In summary, proctocolectomy with ileoanal
pouch for UC is often not the final solution. At
present, it remains the best possible solution for
patients with ‘intractable’ UC, preferably after
exhaustion of all medical options. Patients should
be informed, however, about what to expect after
this surgery in terms of quality of life, potential
complications and need for further drug treatment.
Winslow indeed reported that issues such as diet,
sexual function and returning to work are often
neglected in the discussion with patients who need
to make choices regarding IPAA surgery.40 Quality
of life has also been reported to improve with
infliximab treatment, but no direct comparisons
with surgery have been performed.41
Anti-TNF antibodies are less effective in UC than
in Crohn’s disease (CD)
The reluctance to use anti-TNF antibodies in UC is
often based on the (subjective) assumption that
infliximab works better in CD than in UC.
However, the three major controlled trials which
examined the effect of infliximab in luminal
(ACCENT I) and fistulising (ACCENT II) CD and
in UC (ACT) showed a different picture.29 42 43
Clinical remission rates at 1 year in the three
studies were 35% in the ACT trial, 33% in the
ACCENT-I trial and 36% in the ACCENT-II trial.
Taking into account that patients in the ACT trial
started on the study with more immunosuppres-
sives (50%) and corticosteroids (60%) than patients
in the ACCENT I (33% and 50%) and ACCENT II
trials (33% and 30%), it appears that infliximab is
equally effective in UC and CD. In addition, anti-
body formation against infliximab or low trough
levels might also play a role in the efficacy of
infliximab. In UC and CD there is a lack of data
investigating the influence of trough levels or
antibody formation; however, in rheumatoid
arthritis, the clinical response to infliximab closely
follows the trough drug levels and the presence
of antibodies directed against the drug.44
Mucosal healing rates were also comparable in all
trials. In another trial with patients refractory to
intravenous steroids or whose only alternative
was colectomy, infliximab led to complete clinical
and endoscopic remission in 40% (6/15) of all
patients.45
The efficacy of another anti-TNF antibody,
adalimumab (Humira, Abbott), in UC was less
convincing.46 In a trial with a design similar to the
ACT trials, 8 week remission rates were only 19%
in the study group that received adalimumab every
other week versus 9% in the placebo group. Long-
term results for this trial are being awaited. Novel
biologicals such as golimumab (another anti-TNF
antibody) and vedolizumab (a humanised mono-
clonal antibody against the a4-b7-integrin) are
currently being tested in UC.
In conclusion, at least for infliximab the efficacy
of biological treatment has been comparable with
that in CD.
Mucosal healing is not so important in UC
Mucosal healing has recently become a pivotal
therapeutic goal in CD as well as in UC. Mucosal
healing had been defined by the International
Organization of IBD (IOIBD)47 as the absence of
friability, blood, erosions and ulcers in all visualised
segments of the colonic mucosa. The majority of
clinical trials used this definition, although disap-
pearance of the normal vascular pattern is usually
considered compatible with mucosal healing.
Prospective studies in CD48 and retrospective
studies in UC49 have already confirmed the benefit
of early and sustained mucosal healing for the
patients’ global health. In the recent Norwegian
study by Frøslie et al,49 the authors examined the
impact of mucosal healing on the subsequent
course of disease in >350 patients with UC, before
biological treatment was available. Mucosal healing
after 1 year of treatment was significantly associ-
ated with a low risk of colectomy of 2% at 5 years.
Patients without mucosal healing were colectom-
ised 3.5 times more frequently. Most interestingly,
this association was independent from the clinical
disease course within the 5 years of observation
(remission after initial activity, continuous activity,
relapsing disease or accelerating disease activity).
The follow-up study50 of Järnerot’s infliximab
trial45 achieved a similar result: none of eight
patients in endoscopic remission at 3 months had
a colectomy within a follow-up period of 3 years,
compared with 50% of patients who were not in
remission (p¼0.02).
Achievement of mucosal healing has been asso-
ciated with better outcomes, less surgery and less
hospitalisation. An analysis of the Leuven cohort of
patients with UC treated with infliximab showed
that colectomy was more frequent if patients
did not achieve mucosal healing at week 4 or 10.51
In one subanalysis of the ACT trials, it was
shown that patients treated with infliximab were
less likely to undergo colectomy during 54 weeks
than those receiving placebo.52 As mentioned
above, in another subanalysis of the ACT data,
patients with mucosal healing at week 8 were in
remission at week 30 in 48% as compared with
those without mucosal healing who only reached
remission in 10%.30
Consequently, mucosal healing appears to repre-
sent a highly relevant therapeutic end point in
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patients with UC.11 Evaluation of mucosal
inflammation in UC is easy, since the disease is
mostly present in the rectum, and flexible
sigmoidoscopy or proctoscopy is possible even
without extensive bowel cleansing. Furthermore,
faecal calprotectin levels correlate well with endo-
scopically evaluated disease activity and reliably
discriminate inactive from mild disease, moderate
disease and highly active disease.53
In summary, past and ongoing treatment
concepts for ulcerative colitis have only been
moderately successful. Five to 25% of patients still
lose their colon and overall only half of the patients
achieve sustained remission. Reluctance to treat
patients early on with sufficiently potent drug
regimens and with mucosal healing as a therapeutic
goal may offer a partial explanation for this
phenomenon. Future studies on therapeutic strat-
egies should aim at sustained suppression of
inflammation, which perhaps could lead to
a profound change in the course of the disease. In
the meantime physicians should be encouraged to
intensify and maintain treatment until sustained
mucosal healing is reached.
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